Angiopep-2-Functionalized Lipid Cubosomes for Blood-Brain Barrier Crossing and Glioblastoma Treatment

ACS Appl Mater Interfaces. 2024 Mar 13;16(10):12161-12174. doi: 10.1021/acsami.3c14709. Epub 2024 Feb 28.

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain cancer with high malignancy and resistance to conventional treatments, resulting in a bleak prognosis. Nanoparticles offer a way to cross the blood-brain barrier (BBB) and deliver precise therapies to tumor sites with reduced side effects. In this study, we developed angiopep-2 (Ang2)-functionalized lipid cubosomes loaded with cisplatin (CDDP) and temozolomide (TMZ) for crossing the BBB and providing targeted glioblastoma therapy. Developed lipid cubosomes showed a particle size of around 300 nm and possessed an internal ordered inverse primitive cubic phase, a high conjugation efficiency of Ang2 to the particle surface, and an encapsulation efficiency of more than 70% of CDDP and TMZ. In vitro models, including BBB hCMEC/D3 cell tight monolayer, 3D BBB cell spheroid, and microfluidic BBB/GBM-on-a-chip models with cocultured BBB and glioblastoma cells, were employed to study the efficiency of the developed cubosomes to cross the BBB and showed that Ang2-functionalized cubosomes can penetrate the BBB more effectively. Furthermore, Ang2-functionalized cubosomes showed significantly higher uptake by U87 glioblastoma cells, with a 3-fold increase observed in the BBB/GBM-on-a-chip model as compared to that of the bare cubosomes. Additionally, the in vivo biodistribution showed that Ang2 modification could significantly enhance the brain accumulation of cubosomes in comparison to that of non-functionalized particles. Moreover, CDDP-loaded Ang2-functionalized cubosomes presented an enhanced toxic effect on U87 spheroids. These findings suggest that the developed Ang2-cubosomes are prospective for improved BBB crossing and enhanced delivery of therapeutics to glioblastoma and are worth pursuing further as a potential application of nanomedicine for GBM treatment.

Keywords: angiopep-2; blood–brain barrier; cubosomes; glioblastoma; lipid nanoparticles; lyotropic liquid crystalline nanoparticles; monoolein; organ-on-a-chip.

MeSH terms

  • Blood-Brain Barrier / pathology
  • Brain Neoplasms* / pathology
  • Cell Line, Tumor
  • Glioblastoma* / drug therapy
  • Glioblastoma* / pathology
  • Humans
  • Lipids / therapeutic use
  • Nanoparticles* / therapeutic use
  • Peptides*
  • Prospective Studies
  • Temozolomide
  • Tissue Distribution

Substances

  • Angiopep-2
  • Temozolomide
  • Lipids
  • Peptides